Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

The latest attempt focuses on liraglutide, an older, once-daily injectable product in Novo Nordisk's GLP-1 agonist franchise sold as Victoza and Xultophy for diabetes and Saxenda for obesity.

The cases related mainly to Wegovy and Novo Nordisk’s Saxenda formulation of liraglutide ... and Mounjaro (tirzepatide), Lilly’s dual GLP-1/GIP agonist.

The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker Novo Nordisk, confirmed that supply now meets or exceeds both the current ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

While medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they ...

Pursuing the world's first-ever orally-dosed liraglutide KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global ...

A 52-year-old man has knocked his decade-long cocaine addiction on the head after receiving weight-loss injections. The jab ...

Shortages and the sky-high cost of the new weight loss drugs has led to an explosion of compounded alternatives sold online, through telehealth sites and in compounding pharmacies. Unfortunately, most ...

Peptide therapy enhances targeted medicine, utilizing specific peptides for effective treatment of cancer, metabolic disorders, and neurodegenerative diseases.

In the face of abrupt weight loss, one of the most common consequences is hair loss, even after bariatric surgery. Losing ...